No abstract

No abstract

Background & objectives: Glycated hemoglobin level (HbA1c) is widely used for the diagnosis, prognosis and monitoring of therapy in diabetes mellitus patients. The hemoglobin molecule is a part of the non- enzymatic glycation reaction, so it is assumed that the total hemoglobin concentration may have an effect on the HbA1c value along with blood glucose concentrations. Hence this study was done to evaluate the effect of total hemoglobin level on HbA1c value in type 2 diabetes mellitus patients and to find out whether reduced total hemoglobin level is reflected on the HbA1c level giving an erroneous impression on the glycaemic status of the patient. Methods: 100 diagnosed Type 2 Diabetes Mellitus patients were evaluated for their Fasting Blood Sugar (FBS), Total Hemoglobin level and HbA1c level and assessed for any effect of reduced total hemoglobin level on the HbA1c value. Results: It was observed that HbA1c value correlated significantly only with FBS level and total Hemoglobin level was not found to have any effect on the HbA1c value in Type 2 Diabetes Mellitus patients. Interpretation : The factor significantly affecting the HbA1c value is Fasting Blood Sugar level. Hemoglobin level doesn’t seem to be affecting the HbA1c indicating that Hemoglobin is not a significant predictor of HbA1c. Conclusions: This study documented a significant positive relationship between FBS and HbA1c level only. No correlation was found between total Hemoglobin level and HbA1c.Patients with mild to moderate anemia still revealed a high HbA1c value correlating only with the blood sugar status. Bangladesh Journal of Medical Science Vol.19(1) 2020 p.110-113

ConclusionAnti-TPO antibody subsequently leads to hypothyroxinemia, for which it is necessary that cases with high titer of anti-TPO antibody though euthyroid should be meticulously followed up and screened for to detect development of hypothyroidism or SCH, particularly in future pregnancies. However, GDM prevalence was at par with the national figure, but with no significant association of SCH and a high anti-TPO ab titer was found with GDM in our study. Further studies with a larger cohort may establish a causal association between the two most common endocrinological disorders observed in pregnancy.

Oral squamous cell carcinoma is the sixth most common cancer worldwide. Despite the available treatment, the survival rate is poor. The addition of agents to make chemotherapeutics safer and more effective is important. Curcumin is a common Indian spice that has shown anticarcinogenic properties. It has been possible to overcome its poor bio-availability using nanotechnology. We aimed to investigate the adjuvant effect of nanocurcumin (NC ~ 200 nm size) treatment on cetuximab (epidermal growth factor receptor inhibitor) in oral squamous cancer cells (KB 3-1 cell). Cancer cells were cultured and treated for 24 hours with cetuximab and NC, in various doses to find the drugs' half-maximal inhibitory concentration (IC 50 ).Experiments were conducted with a combination dose of both and sensitization treatment with NC before cetuximab with cytotoxicity assessment by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. One-way analysis of variance (ANOVA) was used to compare different treatment groups. We found a concentration-dependent cancer cell death with NC, which was significant compared to cetuximab (p <0.001). The combination treatment group had highly significant cell death (p <0.0001) compared to a single drug, and the NC sensitization caused substantial cell death compared to a single cetuximab treatment (p<0.01). Our study findings indicate the potential chemo-adjuvant effect of NC in oral cancer.